Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The Global Circulation of Seasonal Influenza A (H3N2) Viruses
Colin A. Russell,1Terry C. Jones,1,2,3Ian G. Barr,4Nancy J. Cox,5Rebecca J. Garten,5Vicky Gregory,6Ian D. Gust,4Alan W. Hampson,4Alan J. Hay,6Aeron C. Hurt,4Jan C. de Jong,2Anne Kelso,4Alexander I. Klimov,5Tsutomu Kageyama,7Naomi Komadina,4Alan S. Lapedes,8Yi P. Lin,6Ana Mosterin,1,3Masatsugu Obuchi,7Takato Odagiri,7Albert D. M. E. Osterhaus,2Guus F. Rimmelzwaan,2Michael W. Shaw,5Eugene Skepner,1Klaus Stohr,9Masato Tashiro,7Ron A. M. Fouchier,2Derek J. Smith1,2*
Antigenic and genetic analysis of the hemagglutinin of 13,000human influenza A (H3N2) viruses from six continents during2002–2007 revealed that there was continuous circulationin east and Southeast Asia (E-SE Asia) via a region-wide networkof temporally overlapping epidemics and that epidemics in thetemperate regions were seeded from this network each year. Seedstrains generally first reached Oceania, North America, andEurope, and later South America. This evidence suggests thatonce A (H3N2) viruses leave E-SE Asia, they are unlikely tocontribute to long-term viral evolution. If the trends observedduring this period are an accurate representation of overallpatterns of spread, then the antigenic characteristics of A(H3N2) viruses outside E-SE Asia may be forecast each year basedon surveillance within E-SE Asia, with consequent improvementsto vaccine strain selection.
1 Department of Zoology, University of Cambridge, Cambridge, UK. 2 Department of Virology, Erasmus Medical Centre, Rotterdam, Netherlands. 3 Universitat Pompeu Fabra, Barcelona, Spain. 4 World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia. 5 WHO Collaborating Center for Influenza, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6 WHO Collaborating Centre for Influenza, National Institute for Medical Research (NIMR), London, UK. 7 WHO Collaborating Center for Influenza, National Institute for Infectious Diseases, Tokyo, Japan. 8 Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA. 9 Novartis Vaccines and Diagnostics, Cambridge, MA, USA.
* To whom correspondence should be addressed. E-mail: dsmith{at}zoo.cam.ac.uk
ATIVS: analytical tool for influenza virus surveillance.
Y.-C. Liao, C.-Y. Ko, M.-H. Tsai, M.-S. Lee, and C. A. Hsiung (2009)
Nucleic Acids Res.
37, W643-W646
|Abstract »|Full Text »|PDF »
Environmental transmission of low pathogenicity avian influenza viruses and its implications for pathogen invasion.
P. Rohani, R. Breban, D. E. Stallknecht, and J. M. Drake (2009)
PNAS
106, 10365-10369
|Abstract »|Full Text »|PDF »
The Evolution of Influenza Resistance and Treatment.
D. M. Weinstock and G. Zuccotti (2009)
JAMA
301, 1066-1069
|Full Text »|PDF »
Influenza seasonality: Lifting the fog.
M. Lipsitch and C. Viboud (2009)
PNAS
106, 3645-3646
|Full Text »|PDF »
Epidemiologic Study of Influenza Infection in Okinawa, Japan, from 2001 to 2007: Changing Patterns of Seasonality and Prevalence of Amantadine-Resistant Influenza A Virus.
Y. Suzuki, K. Taira, R. Saito, M. Nidaira, S. Okano, H. Zaraket, and H. Suzuki (2009)
J. Clin. Microbiol.
47, 623-629
|Abstract »|Full Text »|PDF »
Incorporating demographic stochasticity into multi-strain epidemic models: application to influenza A.